Cited by 154Attention Deficit Hyperactivity DisorderSchizophrenia research and treatmentChild and Adolescent Psychosocial and Emotional Development

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort Study

Open access
Chang, Zheng, D’Onofrio, Brian M., Quinn, Patrick D., Lichtenstein, Paul, Larsson, Henrik·2016·Biological Psychiatry

Abstract

Background Attention-deficit/hyperactivity disorder (ADHD) is associated with high rates of psychiatric comorbidity, including depression. However, it is unclear whether ADHD medication increases or decreases the risk for depression.Methods We studied all individuals with a diagnosis of ADHD born between 1960 and 1998 in Sweden (N = 38,752). We obtained data for prescription of ADHD medication, diagnosis of depression and other psychiatric disorders, and sociodemographic factors from population-based registers. The association between ADHD medication and depression was estimated with Cox proportional hazards regression.Results After adjustment for sociodemographic and clinical confounders, ADHD medication was associated with a reduced long-term risk (i.e., 3 years later) for depression (hazard ratio = 0.58; 95% confidence interval, 0.51-0.67). The risk was lower for longer duration of ADHD medication. Also, ADHD medication was associated with reduced rates of concurrent depression; within-individual analysis suggested that occurrence of depression was 20% less common during periods when patients received ADHD medication compared with periods when they did not (hazard ratio = 0.80; 95% confidence interval, 0.70-0.92).Conclusions Our study suggests that ADHD medication does not increase the risk of later depression; rather, medication was associated with a reduced risk for subsequent and concurrent depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2016.02.018

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 154

Metadata

Authors
Chang, Z., D’Onofrio, B. M., Quinn, P. D., Lichtenstein, P., & Larsson, H.
Affiliations
  • Karolinska Institutet (SE)
  • Indiana University Bloomington (US)
  • Örebro University (SE)
Corresponding author
Chang, Zheng
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2016-12
Volume
80
Issue
12
Pages
916-922
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2278520419
Cited by
154
References
39
Citations by year
2026: 16 · 2025: 13 · 2024: 21 · 2023: 18 · 2022: 15 · 2021: 15 · 2020: 19 · 2019: 14 · 2018: 12 · 2017: 6 · 2016: 4
FWCI
9.17
Type
journal article
Language
en
Open access
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Vetenskapsrådet
  • National Institutes of Health (UL1TR001108, TL1TR001107)
  • National Institute of Mental Health (R01MH102221)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
attention deficit hyperactivity disorder, ADHD medication, depression, psychiatric comorbidity, duration of drug use, mental illness, long-term risk
MeSH terms
Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Depressive Disorder, Female, Humans, Longitudinal Studies, Male, Middle Aged, Drug Prescriptions, Registries, Risk, Sweden, Time Factors, Adrenergic Uptake Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review